Glucagon-like peptide-1 (GLP-1) and Gastric inhibitory polypeptide (GIP) while Ozempic (Semaglutide) only targets GLP-1.

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for shares of Jazz Pharmaceuticals in a ...

The document outlines various health-related news, including a measles outbreak in Texas and New Mexico, UNICEF's aid crisis ...

Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines. Here's what investors need to know about this small-cap biotech company. Iovance ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Talks of a trade dispute between the United States and Australia over the cost of medicines have no doubt left many ...

One of the biggest hurdles in the sugar and ethanol industries is strict government regulations on wastewater management, ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.

Soliman said consumers could see price increases or shortages of generic drugs in the country. There are some laws that ...

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...